source
- UniQure slated for FDA decision by May 1 as analysts see potential for first Huntington’s disease therapyUniQure said the Food and Drug Administration has set a decision date for its Huntington's disease gene therapy and is likely to hold an advisory committee meeting. The agency indicated a faster‑th…
- Pfizer drops phase 2 pulmonary arterial hypertension candidate amid pipeline cutPfizer has discontinued its phase 2 pulmonary arterial hypertension (PAH) program, PF-07868489, citing business reasons rather than safety or efficacy concerns. The drug, which targets BMP9 inhibi…